Citations

Showing 10 of 107966 citations.

A Histologic Pattern of Nonspecific Interstitial Pneumonia Is Associated with a Better Prognosis Than Usual Interstitial Pneumonia in Patients with Cryptogenic Fibrosing Alveolitis
Daniil, Zoe , Gilchrist, Frances, Hansell, David M., Harris, Jessica , Colby, Thomas V. , Bois, Roland M. du, Nicholson, Andrew G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 160 | Issue: 3 | Pages: 899-905

10.1164/ajrccm.160.3.9903021 | PMID 10471616 Get It

Abstract This study aimed to investigate whether there was a difference in outcome related to histologic pattern in cryptogenic fibrosing alveolitis (CFA) and to see whether there were correlations between clinical and radiologic findings and histology. One hundred thirteen lung biopsies from consecutive patients taken for the diagnosis of diffuse lung disease were reviewed and reclassified using the Katzenstein and Myers criteria for interstitial pneumonias. Patients lacking full investigational data at presentation and those with conditions predisposing to lung fibrosis were excluded, leaving 15 patients diagnosed with nonspecific interstitial pneumonia (NSIP) and 15 with usual interstitial pneumonia (UIP). Clinical and radiologic findings at presentation and serial lung function information and survival status in November 1998 were compared for the two groups. Survival was found to be significantly greater in the NSIP group compared with the UIP group (p < 0.001). This could not be explained by differences in treatment. Patients with UIP showed a progressive deterioration in lung function whereas those with NSIP remained stable. CT scans of patients with UIP showed more fibrosis than those of patients with NSIP (p < 0.011). A histologic diagnosis of NSIP is associated with a better prognosis than UIP. This subclassification of CFA is clinically useful.
Regional Expansion of Oleic Acid–Injured Lungs
Martynowicz, Marek A., Minor, T., Walters, Bruce J., Hubmayr, Rolf D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 160 | Issue: 1 | Pages: 250-258

10.1164/ajrccm.160.1.9808101 | PMID 10390408 Get It

Abstract It has been suggested that dependent regions of an injured lung are collapsed and subject to cyclic reopening and collapse during mechanical ventilation. To test this hypothesis, we measured both temporal and spatial heterogeneity of lobar expansion in oleic acid (OA)–injured dogs. Regional volumes were measured in nine dogs (seven supine and two prone) during closed loop sinusoidal oscillations of the lungs before and after OA injury using the parenchymal marker technique. In contrast to computer tomography, the parenchymal marker technique provides absolute measures of regional tissue dimensions as opposed to relative measures of regional air to liquid content. The experiments generated three major findings: (1) OA injury did not lead to the collapse of dependent lung units at FRC, (2) OA injury did not steepen the vertical gradient in regional lung volumes at FRC, and (3) during sinusoidal oscillation of the OA-injured lungs from FRC, dependent regions did not undergo cyclic reopening and collapse. On the basis of these results, we propose an alternative mechanism for the topographic variability in regional impedances and lung expansion after injury, namely liquid and foam in conducting airways.
Anti-CD86 (B7.2) Treatment Abolishes Allergic Airway Hyperresponsiveness in Mice
Haczku, Angela , Takeda, Katsuyuki , Rédai, Imre, Hamelmann, Eckard , CIESLEWICZ, GREGORY, Joetham, Anthony, Loader, Joan E., Lee, J.J., Irvin, Charles G. , Gelfand, Erwin W., Cieslewicz, G., Gelfand, Erwin W.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 159 | Issue: 5 | Pages: 1638-1643

10.1164/ajrccm.159.5.9711040 | PMID 10228138 Get It

Abstract Allergic sensitization in asthma develops as a consequence of complex interactions between T cells and antigen-presenting cells. We have developed several in vivo models to study allergen-specific T cell and B cell function and their relevance to allergic airway hyperresponsiveness (AHR), focusing on the role of the costimulatory molecules CD80 and CD86. Treatment of mice with anti-CD86, but not anti-CD80, significantly inhibited increased serum levels of ovalbumin (OA)-specific IgE and IgG1, airway eosinophilia, and AHR both after 10 d of OA aerosol exposure (in the absence of adjuvant) and after intraperitoneal sensitization followed by repeated airway challenges. Inhibition of AHR was associated with decreased IL-4 and IL-5 levels in the BAL fluid of sensitized mice, suggesting impaired Th2 function in anti-CD86-treated animals. This effect was not seen when mice received treatment only before allergen challenge, indicating that anti-CD86 acts through inhibition of allergic sensitization and not simply by inhibiting the influx of inflammatory cells. These data suggest that the CD86 costimulatory ligand plays a major role in the development of allergic inflammation and AHR in allergen-challenged mice. Further, this study demonstrates that T–B cell interactions during allergic sensitization are amenable to therapeutic manipulation and that selective blockade of accessory signals can be an effective means for modulating distinct T cell functions.
Sputum Eosinophilia Predicts Benefit from Prednisone in Smokers with Chronic Obstructive Bronchitis
Pizzichini, Emílio , Gibson, Peter G. , Parameswaran, K. , Gleich, Gerald J. , Berman, Les, Dolovich, Jerry, Hargreave, F. E., Pizzichini, Márcia Margaret Menezes

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 158 | Issue: 5 | Pages: 1511-1517

10.1164/ajrccm.158.5.9804028 | PMID 9817701 Get It

Abstract A reliable predictor of benefit from corticosteroid treatment in patients with chronic airflow limitation is needed. In a single-blind, sequential crossover trial of placebo and prednisone (30 mg/day) treatment, with each given for 2 wk, we investigated whether an increased proportion of sputum eosinophils ( ≥ 3%) predicts a beneficial effect of prednisone in smokers with severe obstructive bronchitis. Patients were seen before and after each treatment. Clinical measurements were made blind to the laboratory findings and vice-versa. Eighteen of 20 patients completed the study. Eight had sputum eosinophilia and similar clinical and physiologic characteristics to those of 10 patients without a finding of sputum eosinophilia. Only in patients with sputum eosinophilia did prednisone, as compared with placebo, produce a statistically significant and clinically important mean effect on effort dyspnea of 0.8 (95% confidence interval [CI]: 0.3 to 1.2), p = 0.008, and in quality of life of 1.96 (95% CI: 0.5 to 3.3), p = 0.01, associated with a small improvement in FEV1 of 0.11 L (95% CI: − 0.04 to 0.23 L), p = 0.05. In these patients, prednisone also produced a significant decline in the median sputum eosinophil percentage, from 9.7% to 0.5% (p = 0.002), eosinophil cationic protein (ECP), from 6,000 μ g/L to 1,140 μ g/L (p < 0.001), and fibrinogen, from 25.3 mg/L to 5.4 mg/L (p < 0.001). These findings indicate that in smokers with severe airflow limitation, sputum eosinophilia predicts a beneficial effect of prednisone treatment. Improvement in FEV1, after prednisone treatment in this population, is small, and may not be appreciated in clinical practice.
Effect of Zafirlukast (Accolate) on Cellular Mediators of Inflammation: Bronchoalveolar Lavage Fluid Findings after Segmental Antigen Challenge
Calhoun, William J. , Lavins, Bernard J., Minkwitz, Margaret, Gleich, Gerald J. , Cohn, J., Evans, Roger G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 157 | Issue: 5 | Pages: 1381-1389

10.1164/ajrccm.157.5.9609014 | PMID 9603112 Get It

Abstract The effect of zafirlukast (Z) to alter the inflammatory response to segmental antigen challenge (SAC) was assessed by bronchoalveolar lavage (BAL) in this double-blind, placebo-controlled, two-period, crossover trial in 11 allergic asthmatic patients. Patients with asthma and positive skin tests to antigen received 7 d of treatment with Z (20 mg twice daily) or placebo (P) during two trial periods 14 to 21 d apart. At steady state (Day 5), patients underwent SAC followed by BAL immediately after challenge and 48 h later. Purified alveolar macrophages were analyzed ex vivo for phorbol myristate acetate (PMA)-driven superoxide release. Results were analyzed by analysis of variance (ANOVA). Forty-eight hours after SAC, Z therapy was associated with significantly reduced BAL lymphocytes and alcian blue–positive cells (presumably basophils) compared with P (p < 0.01), with a trend toward reduced numbers of alveolar macrophages (p = 0.06). PMA-driven superoxide release by purified alveolar macrophages was significantly reduced 48 h after SAC in the Z versus P arms (p < 0.05). Reduction of basophil influx, mediator release, and cellular activation may be important in attenuating the late phase of asthma. Collectively, the data suggest that zafirlukast therapy alters cellular infiltration and activation associated with antigen challenge.
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
Katzenstein, Anna-Luise A., Myers, Jeffrey L.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 157 | Issue: 4 | Pages: 1301-1315

10.1164/ajrccm.157.4.9707039 | PMID 9563754 Get It

Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
Bjoraker, Julie A., Ryu, Jay H. , Edwin, Mark, Tazelaar, Henry D. , Schroeder, Darrell R. , Offord, Kenneth P., Myers, Jeffrey L. , Tazelaar, Henry D. , Ryu, Jay H , Schroeder, Darrell

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 4, 2013 | Volume: 157 | Issue: 1 | Pages: 199-203

10.1164/ajrccm.157.1.9704130 | PMID 9445300 Get It

Abstract Idiopathic pulmonary fibrosis (IPF) is a generally fatal disorder with a reported median survival of 3 to 6 yr. This has been based on relatively few studies with diagnoses inconsistently confirmed by adequate lung biopsy. Retrospective analysis of 104 patients with IPF who had open lung biopsy (OLB) at Mayo Medical Center from 1976 to 1985 was performed to establish the overall survival rate, the spectrum of histopathological subgroups and their associated prognostic significance. The study group consisted of 54 men and 50 women with a median age of 63 yr. Median survival was 3.8 yr after diagnosis by OLB with an estimated 10 yr survival of 27%. Current histopathologic review showed a heterogeneous group including usual interstitial pneumonia (UIP), desquamative interstitial pneumonia (DIP), nonspecific interstitial pneumonia/fibrosis (NSIP), acute interstitial pneumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), and others. Median survival of the UIP group was 2.8 yr which is significantly worse (p < 0.001) than for other subgroups of chronic interstitial pneumonias. IPF includes several histopathologic subgroups with significantly different survival rates. Patients with UIP have worse survival than patients with other types of idiopathic chronic interstitial pneumonias including NSIP. Accurate histopathologic classification is essential for prognostication in patients with IPF.
Faculty Opinions recommendation of Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.
Jelinek, Diane F., Greenberg, Alexandra J.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 4, 2013 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.717980637.793473412 Get It

The relation between cancer patient treatment decision‐making roles and quality of life
Atherton, Pamela J., Singh, Jasvinder A. , Huntington, J, Diekmann, Brent, Huschka, Mashele , Sloan, Jeff A. , Atherton, Philip J. , Atherton, Pamela J., Smith, Tenbroeck G , Singh, Jasvinder A , Atherton, Philip J.

Mayo Clinic

Cancer | April 4, 2013 | Volume: 119 | Issue: 12 | Pages: 2342-2349

10.1002/cncr.28046 | PMID 23558408 Get It

BACKGROUNDThe objective of this study was to explore relations between patient role preferences during the cancer treatment decision‐making process and quality of life (QOL).METHODSOne‐year cancer survivors completed a survey in 2000 as part of a larger survey conducted by the American Cancer Society. The current report was based on survey respondents from Minnesota (response rate, 37.4%). Standardized measures included the Profile of Mood States (scores were converted to have a range, from 0 to 100, with 100 indicating the best mood), the Medical Outcomes Survey 36‐item short‐form health survey (SF‐36) (standardized scores), and the Control Preferences Scale. Patients' actual and preferred role preference distributions and concordance between roles were compared with QOL scores using 2‐sample t test methodology.RESULTSThe actual role of survivors (n = 594) in cancer care was 33% active, 50% collaborative, and 17% passive. Their preferred role was 35% active, 53% collaborative, and 13% passive. Overall, 88% of survivors had concordant preferred and actual roles. Survivors who had concordant roles had higher SF‐36 Physical Component Scale (PCS) scores (P < .01), higher vitality (P = .01), less fatigue (P < .01), less confusion (P = .01), less anger (P = .046), and better overall mood (P = .01). These results were similar among both women and younger individuals (aged <60 years). Survivors who had active actual roles had higher PCS scores (P < .01), less tension (P = .04), and higher vitality (P = .04) than survivors who were either collaborative or passive. No differences existed in QOL scores according to preferred role.CONCLUSIONSSurvivors who experienced discordance between their actual role and their preferred role reported substantial QOL deficits in both physical and emotional domains. These results indicate the need to support patient preferences. Cancer 2013;119:2342–2349. © 2013 American Cancer Society.
Identification of an Influenza A H1N1/2009 Virus with Mutations in the Matrix Gene Causing a Negative Result by a Commercial Molecular Assay
Binnicker, Matthew J. , Grys, Thomas E. , Espy, Mark J., Hata, D. Jane , Wotton, Jason T., Patel, Robin , Baddour, Larry M. , Patel, Robin , Grys, Thomas E

Mayo Clinic

Journal of Clinical Microbiology | April 4, 2013 | Volume: 51 | Issue: 6 | Pages: 2006-2007

10.1128/jcm.00446-13 | PMID 23554187 Get It